Matthias Dierl - Ion Beam Chief Therapy

All Insiders . USA . 
Stock . Ion Beam Applications . Stakeholders . Insider . Matthias Dierl
IOBCF Stock  USD 13.58  0.47  3.35%   

Insider

Matthias Dierl is Chief Therapy of Ion Beam Applications
Phone32 1 047 58 11
Webhttps://www.iba-worldwide.com

Ion Beam Management Efficiency

The company has return on total asset (ROA) of 0.0203 % which means that it generated a profit of $0.0203 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0368 %, meaning that it generated $0.0368 on every $100 dollars invested by stockholders. Ion Beam's management efficiency ratios could be used to measure how well Ion Beam manages its routine affairs as well as how well it operates its assets and liabilities.
Ion Beam Applications has accumulated 29.94 M in total debt with debt to equity ratio (D/E) of 0.67, which is about average as compared to similar companies. Ion Beam Applications has a current ratio of 1.1, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Ion Beam until it has trouble settling it off, either with new capital or with free cash flow. So, Ion Beam's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ion Beam Applications sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ion to invest in growth at high rates of return. When we think about Ion Beam's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Gregory AhlbergAbbott Laboratories
54
Philip BoudreauAbbott Laboratories
51
Elisabeth StaudingerSiemens Healthineers AG
53
Carsten BertramSiemens Healthineers AG
N/A
Andre HartungSiemens Healthineers AG
N/A
Michael RomanAbbott Laboratories
61
Shez PartoviKoninklijke Philips NV
54
Vance BrownBoston Scientific Corp
54
Todd BrintonEdwards Lifesciences Corp
N/A
Charles BrynelsenAbbott Laboratories
63
Sally SabaMedtronic PLC
N/A
Carrie NicholZimmer Biomet Holdings
40
Kevin LoftonMedtronic PLC
65
Paul StellatoZimmer Biomet Holdings
49
Marc KoebernickSiemens Healthineers AG
N/A
Mary MorelandAbbott Laboratories
58
Michael DaleAbbott Laboratories
61
John GinascolAbbott Laboratories
62
Sean CarneyKoninklijke Philips NV
N/A
Preston WellsStryker
N/A
Sean LennonMedtronic PLC
N/A
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium. ION Beam operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 1668 people. Ion Beam Applications [IOBCF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity0.0368
Return On Asset0.0203

Ion Beam Applications Leadership Team

Elected by the shareholders, the Ion Beam's board of directors comprises two types of representatives: Ion Beam inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ion. The board's role is to monitor Ion Beam's management team and ensure that shareholders' interests are well served. Ion Beam's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ion Beam's outside directors are responsible for providing unbiased perspectives on the board's policies.
Olivier Lechien, Co Director
Pierre Mottet, Chairman, Chairman of Nomination Committee and Chairman of Compensation Committee
Soumya Chandramouli, CFO, Member of the Management Board
Marc Burght, Ex Installation
Matthias Dierl, Chief Therapy
Yves Jongen, Founder, Chief Research Officer, Executive Director and Member of Nomination Committee
Olivier Legrain, CEO and President Executive Director and Member of Nomination Committee
Frederic Nolf, Group Vice President of Human Resources

Ion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ion Beam a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0368
Return On Asset0.0203
Profit Margin0.01 %
Operating Margin0.05 %
Current Valuation338.19 M
Shares Outstanding29.15 M
Shares Owned By Insiders29.13 %
Shares Owned By Institutions27.72 %
Price To Earning9.16 X
Price To Book4.53 X

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Ion Pink Sheet

Ion Beam financial ratios help investors to determine whether Ion Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ion with respect to the benefits of owning Ion Beam security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY